Third Quarter 2026
Filed Nov 2, 2026Celanese Corporation Reports Third Quarter Earnings; Exceeds Third Quarter Guidance and Raises Full Year Outlook
Third-quarter net sales increased 6 percent year over year, adjusted EPS was $1.65, and free cash flow was $461 million. The Company raised its full-year free cash flow outlook to a range of $750 to $800 million, while fourth-quarter expectations include year-end seasonal moderation across both businesses.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $2.56B | 7 percent decrease | 6 percent |
| Cost of sales, three months ended September 30, 2026GAAP | −$2.02B | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $539M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | −$248M | – | – |
| Amortization of intangible assets, three months ended September 30, 2026GAAP | −$40M | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | −$29M | – | – |
| Other (charges) gains, net, three months ended September 30, 2026GAAP | −$32M | – | – |
| Operating profit, three months ended September 30, 2026GAAP | $198M | – | – |
| Operating profit margin, third quarter 2026GAAP | 8 percent | – | – |
| Net earnings, three months ended September 30, 2026GAAP | $78M | – | – |
| Net earnings attributable to Celanese Corporation, three months ended September 30, 2026GAAP | $74M | – | – |
| Diluted EPS, continuing operations, three months ended September 30, 2026GAAP | $0.68 | – | – |
| Diluted EPS, total, three months ended September 30, 2026GAAP | $0.67 | – | – |
| Adjusted EPS, three months ended September 30, 2026non-GAAP | $1.65 | – | – |
| Adjusted EBIT, three months ended September 30, 2026non-GAAP | $367M | – | – |
| Adjusted EBIT margin, third quarter 2026non-GAAP | 14 percent | – | – |
| Operating EBITDA, three months ended September 30, 2026non-GAAP | $548M | – | – |
| Operating EBITDA margin, third quarter 2026non-GAAP | 21 percent | – | – |
| Net cash provided by operating activities, three months ended September 30, 2026GAAP | $538M | – | – |
| Free cash flow, three months ended September 30, 2026non-GAAP | $461M | – | – |
| Net cash provided by investing activities, three months ended September 30, 2026GAAP | −$70M | – | – |
| Net cash provided by financing activities, three months ended September 30, 2026GAAP | −$480M | – | – |
| Effective U.S. GAAP income tax rate, third quarter 2026GAAP | 15 percent | – | – |
| Effective tax rate for 2026 adjusted earnings, third quarter 2026non-GAAP | 8 percent | – | – |
| Year to date operating cash flow, 2026GAAP | $823M | – | – |
| Year to date free cash flow, 2026non-GAAP | $604M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Engineered MaterialsContinued momentum in strategic growth initiatives and disciplined commercial execution. Growth in medical and electronics applications supported favorable mix enrichment and earnings improvement, while sequential automotive declines weighed on sales. | $1.37B | 5 percent decrease | 1 percent decrease |
| Acetyl ChainModest demand softness was more than offset by pricing favorability and incremental spot opportunities across acetic acid, derivatives, and the vinyls chain. Sequential moderation reflected normalizing supply chains. | $1.21B | 9 percent decrease | 14 percent increase |
| Intersegment EliminationsIntersegment eliminations reported in consolidated net sales. | −$21M | – | – |
Full-year 2026 outlook
- Tax rate8 percent
- NoteAdjusted earnings per share of approximately $6.00 to $6.25
- NoteFree cash flow outlook to a range of $750 to $800 million
- NoteNet debt-to-operating EBITDA of approximately 4.7x
- NoteApproximately $650 million of divestiture sales proceeds by year end
- NoteOver $1.5 billion in free cash flow over the past two years by the end of 2026
What drove it
- Portfolio-wide strategic growth initiatives and commercial actions drove the 6 percent increase in consolidated net sales compared with the same period in 2025.
- Engineered Materials results were supported by commercial execution, favorable product mix, and early contributions from strategic growth initiatives, which more than offset raw material inflation and higher logistics costs.
- Medical and electronics applications supported Engineered Materials mix enrichment and earnings improvement.
- Acetyl Chain pricing favorability and incremental spot opportunities more than offset modest demand softness.
- The Acetyl Chain cited its integrated business model and flexible operating network as sources of value capture across regions.
- Cash flow reflected anticipated working capital timing benefits and continued capital-expenditure discipline.
Concerns
- Fourth-quarter expectations include year-end seasonal moderation across both businesses.
- Engineered Materials sequential sales declined mainly because of sequential automotive declines.
- Acetyl Chain sequential sales declined as supply chains normalized.
- Raw material inflation and higher logistics costs affected Engineered Materials, though they were more than offset during the quarter.
- The prior-year third-quarter results included a non-cash goodwill impairment loss of $1.1 billion in Engineered Materials that was not deductible for tax purposes.
- The Company stated that conditions remain dynamic.
What to watch
- Fourth-quarter seasonal moderation across Engineered Materials and the Acetyl Chain.
- Delivery against full-year adjusted EPS of approximately $6.00 to $6.25 and free cash flow of $750 to $800 million.
- Progress toward net debt-to-operating EBITDA of approximately 4.7x at year end.
- Closing of the Nutrinova transaction and the expected approximately $650 million of divestiture sales proceeds by year end.
- Commercialization during the first half of 2027 of specialty compounding expansions in Europe, a liquid crystal polymer production facility in Asia, and medical-grade compounding capabilities in Asia.
- The Investor Event scheduled for December 9, 2026, where executive management plans to provide business-strategy, growth-pathway, and long-term-value-creation details.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $1,362 million, compared with $1,263 million as of December 31, 2025.
- Short-term borrowings and current installments of long-term debt as of September 30, 2026: $1,414 million, compared with $1,204 million as of December 31, 2025.
- Long-term debt, net of unamortized deferred financing costs, as of September 30, 2026: $10,131 million, compared with $11,394 million as of December 31, 2025.
- Total assets as of September 30, 2026: $20,934 million, compared with $21,695 million as of December 31, 2025.
- Total Celanese Corporation shareholders' equity as of September 30, 2026: $4,216 million, compared with $4,049 million as of December 31, 2025.
- Third-quarter operating cash flow was $538 million and free cash flow was $461 million, supported by anticipated working capital timing benefits and continued discipline in capital expenditures.
- The Company signed a definitive agreement to sell an additional 19 percent of the Nutrinova food ingredients joint venture for total cash proceeds of approximately $152 million, while retaining an 11 percent interest. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary closing conditions.
Analysis
Celanese reported third-quarter net sales of $2,556 million, up 6 percent compared with the same period in 2025, but down 7 percent sequentially. U.S. GAAP diluted EPS from continuing operations was $0.68 and adjusted EPS was $1.65. Consolidated operating profit was $198 million, adjusted EBIT was $367 million, and operating EBITDA was $548 million, with reported margins of 8 percent, 14 percent, and 21 percent, respectively. The prior-year comparison includes a $1.1 billion non-cash goodwill impairment loss in Engineered Materials.
Engineered Materials generated net sales of $1,368 million, a 1 percent decrease year over year and a 5 percent decrease sequentially. Management said that 2025 sales included the divested Micromax business, which contributed 6 percent to the year-over-year decline. Medical and electronics growth supported mix enrichment, while sequential automotive declines were the main headwind. The segment delivered operating profit of $161 million, adjusted EBIT of $209 million, and operating EBITDA of $311 million, supported by commercial execution, favorable mix, and early strategic-growth contributions.
Acetyl Chain was the principal source of top-line growth, with net sales of $1,209 million, up 14 percent compared to the same period in 2025. Sales declined 9 percent sequentially as supply chains normalized. Modest demand softness was more than offset by pricing favorability and incremental spot opportunities across acetic acid, derivatives, and the vinyls chain. The segment reported operating profit of $141 million, adjusted EBIT of $236 million, and operating EBITDA of $301 million.
Cash generation was a central feature of the quarter. Operating cash flow was $538 million and free cash flow was $461 million, while year-to-date operating cash flow and free cash flow were $823 million and $604 million, respectively. Cash and cash equivalents were $1,362 million as of September 30, 2026, while long-term debt was $10,131 million. The Company also expects to exit the year with net debt-to-operating EBITDA of approximately 4.7x and expects approximately $650 million in divestiture sales proceeds by year end.
Management raised its full-year 2026 free cash flow outlook to $750 to $800 million and guided to adjusted EPS of approximately $6.00 to $6.25. The Company expects year-end seasonal moderation in the fourth quarter across both businesses. Investors should focus on whether pricing, commercial actions, productivity initiatives, and strategic growth projects can offset the stated moderation, automotive softness, raw-material inflation, and logistics costs while supporting the planned deleveraging trajectory.
Management, verbatim
Our third quarter results demonstrate continued progress across Celanese, with strong earnings performance and net sales growth. Cash generation in the third quarter was strong, and by the end of 2026 we expect to have generated over $1.5 billion in free cash flow over the past two years, reflecting the benefits of the significant actions we have taken to improve productivity, strengthen commercial execution and enhance the quality of our portfolio.
Scott Richardson, president and chief executive officer
Looking to the fourth quarter, we expect year-end seasonal moderation across both businesses. We will continue to drive our strategic initiatives, our targeted growth areas, as well as our cost reduction and productivity programs.
Scott Richardson, president and chief executive officer
While conditions remain dynamic, the progress we are seeing across our productivity initiatives, strategic growth platforms, and cash generation efforts give us confidence in our ability to continue improving the earnings power of the company over time.
Scott Richardson, president and chief executive officer
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so comparisons of actual results with prior guidance are unavailable.
- Full-year 2026 revenue guidance was not provided.
- Full-year 2026 gross margin guidance was not provided.
- Full-year 2026 operating-expense guidance was not provided.
- Dividend information was not reported.
- Share repurchase information was not reported.
- A prior-year effective U.S. GAAP income tax rate was not provided.
- Prior-year and prior-quarter values for reported operating profit, adjusted EBIT, and operating EBITDA margins were not provided.
- Year-over-year and sequential percentage changes for most income-statement and cash-flow line items were not printed.
- A reported net debt amount was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.